Acesso livre
Acesso livre

Farmácia/Notícias da Indústria

O uso e o impacto de anticorpos monoclonais biológicos durante a gestação.

28 Jul, 2021 | 09:47h

The use and impact of monoclonal antibody biologics during pregnancy – Canadian Medical Association Journal

[Preprint] Covid-19: intervalo mais longo entre as doses da vacina da Pfizer aumenta a resposta imune.

27 Jul, 2021 | 10:34h

Comunicado de imprensa: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University

Estudo original (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine

Comentários:

Commentary: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds – BMJ

Expert reaction to preprint from PITCH study looking at interval between two Pfizer vaccine doses, and antibody and T-cell responses – Science Media Centre

Conteúdo Relacionado:

Debate: Should we delay second vaccine doses to give one dose of the Covid-19 vaccine to more people? (vários textos sobre o tema)

Outro estudo mostra resposta imune aumentada com vacinação heteróloga Oxford-AstraZeneca/mRNA.

27 Jul, 2021 | 10:32h

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine

Comentário: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine

Conteúdos Relacionados:

WHO warns against mixing and matching COVID vaccines.

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Avaliação da segurança da segunda dose de vacinas de mRNA contra COVID-19 em pacientes com reações alérgicas na primeira dose.

27 Jul, 2021 | 10:27h

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose – JAMA Internal Medicine

Comentários:

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose – Massachusetts General Hospital

No anaphylaxis after second dose of mRNA COVID vaccine, study finds – CIDRAP

 

Comentário no Twitter

 

[Preprint] Estudo observacional | Efetividade da vacina Oxford-AstraZeneca em idosos durante a transmissão da variante Gama do SARS-CoV-2 no Brasil – A efetividade ajustada foi de 77,9% para Covid-19 sintomática, 87,6% contra hospitalização e 93,6% contra morte.

27 Jul, 2021 | 10:26h

Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil – medRxiv

 

Comentário no Twitter (fio – clique para saber mais)

 

[Preprint] Estudo observacional | Efetividade da vacina CoronaVac em idosos durante a transmissão da variante Gama do SARS-CoV-2 no Brasil – A efetividade ajustada foi de 41,6% para Covid-19 sintomática, 59% contra hospitalização e 71,4% contra morte.

27 Jul, 2021 | 10:25h

Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – medRxiv

 

Comentário no Twitter (fio – clique para saber mais)

 

Vacina CoronaVac: os resultados são conflitantes, mas o mundo não pode ignorar sua utilidade.

27 Jul, 2021 | 10:23h

CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness – The Conversation

Conteúdos Relacionados:

RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.

Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

Perspective | Are Chinese COVID vaccines underperforming? a dearth of real-life studies leaves unanswered questions.

WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.

Brazilian town experiment shows mass vaccination can wipe out COVID-19.

WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations.

[Press release – not published yet] The city of Serrana in Brazil has seen a 95% drop in Covid-19 deaths after almost all adults were vaccinated with Chinese CoronaVac – The findings suggest the pandemic can be controlled after 75% of people are fully vaccinated.

[Not published yet] Observational study in Uruguay found CoronaVac reduced mortality by 97 percent – “In people who had received two doses, it reduced infection with the coronavirus by 57 percent and intensive care admissions by 95 percent”.

[Preprint] RCT: Em pacientes com COVID-19 e hipóxia grave, a dexametasona 12 mg NÃO resultou em melhora estatisticamente significativa nos desfechos em comparação com a dexametasona 6 mg – “A mortalidade em 28 dias foi de 27,1% e 32,3% em pacientes atribuídos a 12 mg e 6 mg, respectivamente (risco relativo ajustado 0,86, 99% IC, 0,68-1,08).”

26 Jul, 2021 | 10:24h

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial – medRxiv

Entre receptores de transplante de rim que não tiveram resposta imune adequada a 2 doses, uma terceira dose de vacina mRNA induziu resposta sorológica em 49% dos pacientes.

26 Jul, 2021 | 10:18h

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses – JAMA

Comentário: Case Mounts for COVID Vaccine Boosters in Kidney Transplant Recipients – MedPage Today (necessário cadastro gratuito)

Relacionado:

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

 

Comentário no Twitter

 

Editorial | Uso excessivo de antibióticos: gerenciamento da incerteza e mitigação contra o tratamento em excesso.

26 Jul, 2021 | 09:58h

Antibiotic overuse: managing uncertainty and mitigating against overtreatment – BMJ Quality & Safety

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.